Dr. Reggia, et al, reply

Affiliations

¹ Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy. rossella.reggia@gmail.com.
² Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy.

Comment

Rossella Reggia et al. J Rheumatol. 2015 Oct.

. 2015 Oct;42(10):1995.

doi: 10.3899/jrheum.150688.

¹ Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy. rossella.reggia@gmail.com.
² Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy.

No abstract available

Comment on

Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety.
Reggia R, Franceschini F, Tincani A, Cavazzana I. Reggia R, et al. J Rheumatol. 2015 Feb;42(2):193-5. doi: 10.3899/jrheum.141042. Epub 2014 Dec 15. J Rheumatol. 2015. PMID: 25512476
Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients.
Monti S, Breda S, Grosso V, Todoerti M, Montecucco C, Caporali R. Monti S, et al. J Rheumatol. 2015 Oct;42(10):1993-4. doi: 10.3899/jrheum.150230. J Rheumatol. 2015. PMID: 26429207 No abstract available.